Because of the sale of shares by company insiders, the price of Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) dropped by 4.5% on Friday. The share price has fluctuated between $16.25 and $16.29 over the past few days. During trading, 1,765 shares were transacted, which is a decline of 100% compared to the average session volume of 362,124 shares. Earlier, the share price had finished the day at $17.05. On November 29th, Company Director Barry D. Quart completed the sale of 21,959 shares of the company’s stock. At an average price of $16.15, the shares brought in a total of $354,637.85 when sold. The transaction was made public by a legal filing with the Securities and Exchange Commission, which may be located here for your perusal. Insiders own 54.57% of the business currently in operation.

The firm’s market capitalization is $1.13 billion, the price-to-earnings ratio is 8.53, and the beta value is -0.14. The moving average for the company over the past 50 days is $13.87, and the moving average for the last 200 days is $11.60.
In a separate piece of news, a research note published on Friday, November 4th, by TheStreet raised Kiniksa Pharmaceuticals from a rating of “D” to a rating of “C+.”
The company’s investment in hedge funds has undergone significant changes. During the first three months of 2018, Parkman Healthcare Partners LLC added 4.1% more shares to its holdings in Kiniksa Pharmaceuticals. After making additional purchases during the period, Parkman Healthcare Partners LLC now possesses a total of 118,247 shares of the business, which are currently valued at $1,170,000. In addition, during the first three months of 2018, Rice Hall James & Associates LLC boosted the percentage of Kiniksa Pharmaceuticals stock is owned by 13.9%. Following the acquisition of 99,115 shares during the period, Rice Hall James & Associates LLC now holds 811,922 shares of the company’s stock, valued at $8,071,000. During the second quarter, Walleye Capital LLC grew its position in Kiniksa Pharmaceuticals by 191.2%. Walleye Capital LLC now has 295,923 shares of the company’s stock, valued at $2,867,000 after the acquisition of an additional 194,313 shares during the time in question. In addition, Lazard Asset Management LLC grew its holdings in Kiniksa Pharmaceuticals by 84.4% during the second quarter of this year. Following the acquisition of 4,826 shares during the reporting period, Lazard Asset Management LLC now has 10,546 shares of the company’s stock. The value of these shares is currently $102,000.
Last but not least, Great Point Partners LLC grew its holdings in Kiniksa Pharmaceuticals by 108.3% over the first three months of the year. As a result, great Point Partners LLC now has a total of 1,118,067 shares, valued at $11,114,000. This was accomplished by acquiring an additional 581,329 shares during the period. Institutional investors and hedge funds currently own 43.22% of the company’s shares.

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focusing on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. The company’s primary market is the global market for patients suffering from these diseases. Interleukin-1 alpha and beta inhibitors Arcalyst has completed Phase II clinical trials to treat recurrent pericarditis, an inflammatory cardiovascular illness. These trials were conducted to determine whether or not ARCALYST might effectively treat the condition. In addition, Mavrilimumab, a monoclonal antibody inhibitor, has successfully finished Phase II clinical studies to treat giant cell arteritis. Additionally, vixarelimab, another monoclonal antibody, is currently in Phase 2a clinical trials to treat prurigo nodularis.

The post Kiniksa Pharmaceuticals (NASDAQ:KNSA) is down 4.5% as a result of insider selling. appeared first on Best Stocks.